Brind.
  1. BioMarin Pharmaceutical announced on August 5, 2025, that an acquisition successfully broadened its enzyme therapies portfolio.

BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.

5 reports, 2 independent Updated Aug 5
Gone quiet Reached 2 outlets in its first 24 hours
Reports
5
Developments
3
Repetition
40%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.

Who's involved

What this event is mainly about
BioMarin Pharmaceutical

How it developed

Newest first. Tap a step to see who reported it.
  1. BioMarin expanded its enzyme therapies portfolio through an acquisition on August 5, 2025.1 source
  2. BioMarin acquired Inozyme Pharma, Inc. with legal counsel Cooley LLP.
  3. BioMarin completed the acquisition of Inozyme Pharma, Inc.

Keep exploring

Part of

BioMarin Pharmaceutical announced on August 5, 2025, that an acquisition successfully broadened its enzyme therapies portfolio. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • PR NewswireBioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS Second Quarter 2025 Total Revenues of $825 m
  • GuruFocus.comBioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... Total Revenue Growth: 16% increase in Q2 2025 compared to Q2 2024. VOXZOGO Revenue: Increased 20% ye
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet